Discoveries from ASRS

A review of guidelines for neovascular age-related macular degeneration shows a high level of agreement on the use of optical coherence tomography and visual acuity in diagnosis and monitoring.

Ellipsoid zone integrity may be an important biomarker in predicting the progression of geographic atrophy in eyes with dry age-related macular degeneration.

Avacincaptad pegol may help postpone driving restrictions or loss of driving eligibility in patients with geographic atrophy, according to a post hoc analysis of the GATHER1 and GATHER2 trials.

Patients with neovascular age-related macular degeneration who experienced catastrophic vision loss after subretinal hemorrhage were linked to longer anti-VEGF treatment duration and shorter time from prior injection.

Eyes with neovascular age-related macular degeneration that switched to faricimab generally had lower rates of lesion activity, longer treatment intervals and stable visual acuity.

Pegcetacoplan may be a more effective treatment option than avacincaptad pegol for reducing geographic atrophy lesion growth in patients with age-related macular degeneration.

Patients with neovascular age-related macular degeneration who have responded poorly to anti-VEGF monotherapy may require an average of nine injections of faricimab before improvement is seen.

Patient education materials related to age-related macular degeneration treatment are often written at inappropriate reading levels and lack accountability, according to a presentation at the American Society of Retina Specialists meeting.

In this video, Rishi P. Singh, MD, discusses results from part 1 of the phase 2/3 SIGLEC trial assessing AVD-104 for geographic atrophy, presented at the ASRS annual meeting in Stockholm.

Researchers linked higher frequency of intravitreal anti-VEGF injections with a greater risk for mild cognitive impairment in patients with age-related macular degeneration.